LAG3 and melanoma: Recent results in melanoma (phase III RELATIVITY-047 trial) were published at ASCO, revealing that a combination of LAG-3 antibodies with anti-PD-1 increased the progression free survival to 10.1 months compared to nivolumab alone (4.6 months) [79].